Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators
RM Lang,
U Elkayam,
LG Yellen,
D Krauss,
RS McKelvie,
DE Vaughan,
DE Ney,
L Makris,
and
PI Chang
University of Chicago Medical Center, Illinois 60637, USA. rlang@medicine.bsd.uchicago
OBJECTIVES: This study was designed to determine 1) whether 12-week oral administration of losartan, an angiotensin II receptor antagonist, in patients with heart failure is well tolerated; and 2) whether functional capacity and clinical status of patients with heart failure in whom treatment with an angiotensin-converting enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will remain similar to that noted in patients in whom treatment with an ACE inhibitor is continued. BACKGROUND: Losartan is a specific, nonpeptide angiotensin II receptor antagonist. Although specific receptor blockade with losartan has certain theoretic advantages over nonspecific ACE inhibition, definitive demonstration of comparable effects in patients with congestive heart failure is lacking. METHODS: A double-blind, multicenter, randomized, parallel, enalapril-controlled study was conducted in 116 patients with congestive heart failure (New York Heart Association functional classes II to IV) and left ventricular ejection fraction < or = 45% previously treated with stable doses of ACE inhibitors and diuretic agents, with or without concurrent digitalis and other vasodilators. After a baseline exercise period, open-label ACE inhibitors were discontinued, and patients were randomly assigned to 12 weeks of therapy with losartan, 25 mg/day (n = 38); losartan, 50 mg/day (n = 40); or enalapril, 20 mg/day (n = 38). Drug efficacy was evaluated by changes in maximal treadmill exercise time (using a modified Naughton protocol), 6-min walk test, left ventricular ejection fraction and dyspnea-fatigue index. Safety was measured by the incidence of clinical and laboratory adverse experiences. RESULTS: The treadmill exercise time and the 6-min walk test did not change significantly after replacement of ACE inhibitor therapy with losartan. Similarly, a significant change was not observed in either the dyspnea-fatigue index or left ventricular ejection fraction at the end of double-blind period relative to baseline. CONCLUSIONS: Losartan was generally well tolerated and comparable to enalapril in terms of exercise tolerance in this short-term (12-week) study of patients with heart failure. The clinical effects of long-term angiotensin II receptor blockade compared with ACE inhibition remain to be studied.
This article has been cited by other articles:
|
|
|
|
 
D. W. Kitzman, W. G. Hundley, P. H. Brubaker, T. M. Morgan, J. B. Moore, K. P. Stewart, and W. C. Little
A Randomized Double-Blind Trial of Enalapril in Older Patients With Heart Failure and Preserved Ejection Fraction: Effects on Exercise Tolerance and Arterial Distensibility
Circ Heart Fail,
July 1, 2010;
3(4):
477 - 485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. White, H. Ross, S. Levesque, L. Whittom, G. B Pelletier, N. Racine, S. Meloche, and L. Voisin
Effects of Angiotensin-Converting Enzyme Inhibitor Versus Valsartan on Cellular Signaling Events in Heart Transplant
Ann. Pharmacother.,
May 1, 2009;
43(5):
831 - 839.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. White, J.-L. Rouleau, R. Afzal, J. Floras, S. Yusuf, and R. S. McKelvie
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker
Therapeutic Advances in Cardiovascular Disease,
April 1, 2009;
3(2):
113 - 121.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal
Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics,
March 1, 2006;
11(1):
31 - 45.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Dore, C. Houde, K.-L. Chan, A. Ducharme, P. Khairy, M. Juneau, F. Marcotte, and L.-A. Mercier
Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial
Circulation,
October 18, 2005;
112(16):
2411 - 2416.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Olsson, K. Swedberg, A. L. Clark, K. K. Witte, and J. G.F. Cleland
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review
Eur. Heart J.,
April 2, 2005;
26(8):
778 - 793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. C. Lee, D. C. Rhew, M. Dylan, E. Badamgarav, G. D. Braunstein, and S. R. Weingarten
Meta-Analysis: Angiotensin-Receptor Blockers in Chronic Heart Failure and High-Risk Acute Myocardial Infarction
Ann Intern Med,
November 2, 2004;
141(9):
693 - 704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D B McKenzie and A J Cowley
Drug therapy in chronic heart failure
Postgrad. Med. J.,
November 1, 2003;
79(937):
634 - 642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Fink
The Use of Angiotensin-II Receptor Blockers in Heart Failure
Journal of Pharmacy Practice,
August 1, 2002;
15(4):
318 - 325.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Jong, C. Demers, R. S. McKelvie, and P. P. Liu
Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials
J. Am. Coll. Cardiol.,
February 6, 2002;
39(3):
463 - 470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gurlek, M. Kilickap, I. Dincer, R. Dandachi, H. Tutkak, and D. Oral
Effect of Losartan on Circulating TNF{alpha} Levels and Left Ventricular Systolic Performance in Patients with Heart Failure
European Journal of Cardiovascular Prevention & Rehabilitation,
October 1, 2001;
8(5):
279 - 282.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. H. Jamali, W. H. W. Tang, U. N. Khot, and M. B. Fowler
The Role of Angiotensin Receptor Blockers in the Management of Chronic Heart Failure
Arch Intern Med,
March 12, 2001;
161(5):
667 - 672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kumar, D. R. Maurya, M. Chandra, S. Kumar, D. R. Maurya, and M. Chandra
ACE Inhibition Versus Angiotensin-II Antagonism in Heart Failure
Asian Cardiovasc Thorac Ann,
June 1, 2000;
8(2):
195 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. McKelvie, S. Yusuf, D. Pericak, A. Avezum, R. J. Burns, J. Probstfield, R. T. Tsuyuki, M. White, J. Rouleau, R. Latini, et al.
Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure : Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators
Circulation,
September 7, 1999;
100(10):
1056 - 1064.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. P. Brunner-La Rocca, G. Vaddadi, and M. D. Esler
Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism
J. Am. Coll. Cardiol.,
April 1, 1999;
33(5):
1163 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hamroff, S. D. Katz, D. Mancini, I. Blaufarb, R. Bijou, R. Patel, G. Jondeau, M.-T. Olivari, S. Thomas, and T. H. Le Jemtel
Addition of Angiotensin II Receptor Blockade to Maximal Angiotensin-Converting Enzyme Inhibition Improves Exercise Capacity in Patients With Severe Congestive Heart Failure
Circulation,
March 2, 1999;
99(8):
990 - 992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
LOSARTAN AS AN ALTERNATIVE TO ACE INHIBITORS FOR CHF
Journal Watch (General),
October 14, 1997;
1997(1014):
1 - 1.
[Full Text]
|
|
|
|
